Genetic Variations in the Activation and Effector Pathways of Cytotoxic T Lymphocytes Modulate Alloimmune Reactivities and Have Prognostic Significance Following Allogeneic Hematopoietic Stem Cell Transplantation

X. Xiao,Y. Luo,X. Lai,J. Shi,Y. Tan,J. He,W. Xie,W. Zheng,X. Ye,X. Yu,Z. Cai,M. Lin,H. Huang

DOI: https://doi.org/10.1016/j.bbmt.2011.12.427

2012-01-01

Bone Marrow Transplantation

Abstract:Donor T lymphocytes play a critical role in alloimmune reactivities after allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD28, inducible co-stimulator (ICOS) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) belong to the same family of T-cell costimulatory molecules. After activation, three effector pathways have been described for T-cell cytotoxicity: granzyme B/perforin, Fas/Fas ligand (FasL) and secreted molecules such as TNF-alpha. Near recently, several important polymorphisms have been identified in those genes and reported to be associated with the risk of autoimmune diseases, malignancies and allograft rejection in solid organ transplantation patients. However, such information is less available in allo-HSCT. In the present study, we first investigated the influence of those genes polymorphic features on the abilities of T-cell alloimmune responses in allo-HSCT setting. We analyzed 10 single nucleotide polymorphisms (SNPs) in the CD28, ICOS, CTLA-4, Granzyme B, Fas and FasL genes in 138 pairs of recipients and their unrelated donors (URDs) and 102 pairs of recipients and their HLA-identical sibling donors. (1) We found two SNPs in donors influenced the risk of aGVHD. The association was particularly strong in the URD transplantation cohort. Unrelated donor with Granzyme B +55 mutated genotype (AA) was an independent risk factor for grades II-IV aGVHD (P = 0.024, RR = 1.811, 95%CI, 1.080-3.038). While unrelated donor with CTLA-4 CT60 mutated genotype (AA) was protective (P = 0.025, RR = 3.806, 95%CI, 1.187-12.204). (2) However, donor with CTLA-4 CT60 AA genotype was a risk of early CMV infection (P < 0.0001, RR = 0.383, 95%CI, 0.243-0.605) and relapse after allo-HSCT in AML patients (P = 0.047, RR = 2.792 95%CI, 1.013-7.696). Furthermore, AML patients with Fas -670 homogeneous mutated allele (TT genotype) also had a higher risk of relapse (P = 0.003, RR = 3.823 95%CI, 1.566-9.337). (3) The presence of those susceptible alleles in donor and/ or recipient (patients receiving CTLA-4 CT60 AA donor, patients receiving GranzymeB +55 AA donor, AML patients with Fas -670 TT genotype or with all) resulted in a reduced overall survival compared with those with wild-type genotypes (54.9% vs 69.5%, P = 0.029). The results of this study highlight the important effect of genetic variations in T-cell activation and effector pathways from the donors and recipients on the outcomes of allo-HSCT.